60 DEGREES PHARMACEUTICALS, INC. 8-K

What Happened
On March 13, 2026, 60 Degrees Pharmaceuticals, Inc. (SXTP) filed an 8-K attaching an updated legal opinion from counsel regarding the shares of common stock issued and sold under its at-the-market (ATM) equity offering program. The ATM Program is being conducted pursuant to a Sales Agreement dated September 5, 2025 with HC Wainwright & Co., LLC. The updated opinion, filed as Exhibit 5.1, confirms the validity of shares that may be sold under the program and addresses certain legal matters related to offering those shares; it does not change the ATM Program’s terms.

Key Details

• Filing date: March 13, 2026.
• Sales Agreement counterparty: HC Wainwright & Co., LLC (Sales Agreement dated September 5, 2025).
• Document filed: Updated legal opinion of Sichenzia Ross Ference Carmel LLP (Exhibit 5.1) and related consent.
• Effect: Confirms validity of ATM shares and legal matters related to the offering; does not alter ATM Program terms.

Why It Matters
This filing provides legal confirmation that shares sold under the ATM program are validly issued, which reduces legal uncertainty around those offerings. For investors, the filing does not represent new financing or a change to the offering terms — it is an assurance about the legal standing of shares already authorized for sale under the existing ATM arrangement.